Q2 2025 Earnings Call Transcript August 6, 2025 Lexicon Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0 ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a ...

Lexicon Pharmaceuticals ( ($LXRX) ) has released its Q2 earnings. Here is a breakdown of the information Lexicon Pharmaceuticals presented to its ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release. Analysts ...

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates Provided by GlobeNewswire May 13, 2025, 1:00:00 PM ...

Lexicon Pharmaceuticals, Inc. announced that it will release its financial results for the fourth quarter and full year 2024 on March 6, 2025, after market close.

Lexicon Pharmaceuticals (281) 863-3383 klee@lexpharma.com For Media Inquiries: Chas Schultz Executive Director, Corporate Communications and Patient Advocacy Lexicon Pharmaceuticals (281) 863-3421 ...

Lexicon Pharmaceuticals (281) 863-3383 klee@lexpharma.com For Media Inquiries: Chas Schultz Executive Director, Corporate Communications and Patient Advocacy Lexicon Pharmaceuticals (281) 863-3421 ...

Lexicon Pharmaceuticals has a strong cash position and multiple late-stage assets. However, the company is facing low revenues and high expenses. Overall, Lexicon Pharmaceuticals' financial ...

What: Shares of Lexicon Pharmaceuticals , a clinical-stage biopharmaceutical company focused on the development of small-molecule treatments to fight a host of diseases, rocketed higher by as much ...

Summary Lexicon ought to find out whether its heart failure candidate sotagliflozin will be approved on May 27. The drug has been rejected before - in 2019, in patients with Type 1 diabetes, on ...